中国经济网北京6月4日讯双枪科技（001211）(001211.SZ)昨日晚间披露《关于特定股东减持股份的预 披露公告》。 双枪科技于2021年8月5日在深交所主板上市，发行总股数为1800万股，发行价格为26.40元/股，保荐机 构为兴业证券股份有限公司，保荐代表人为李俊、王志。 双枪科技上市第4个交易日，即2021年8月10日，该股开盘报50.60元，创上市以来最高价。该股目前处 于破发状态。 双枪科技首次公开发行股票募集资金总额为4.75亿元，扣除发行费用后，募集资金净额为4.18亿元。双 枪科技最终募集资金净额与原计划一致。双枪科技于2021年7月22日披露的招股说明书显示，该公司拟 募集资金4.18亿元，用于日用餐厨具自动化生产基地建设项目、信息化建设项目、补充流动资金。 双枪科技首次公开发行股票的上市发行费用为5691.08万元，其中兴业证券股份有限公司获得承销及保 荐费用2659.02万元。 根据公告，特定股东宁波科发海鼎创业投资合伙企业(有限合伙)(以下简称"科发海鼎")计划在公告披露 之日起3个交易日后的3个月内通过集中竞价交易方式减持公司股份不超过231,320股，不超过公司总股 本的0. ...

盛帮股份（301233）公告，公司董事、副总经理范德波计划减持不超过11.72万股，占总股本的 0.2310%。董事、副总经理付强计划减持不超过10.5万股，占总股本的0.2069%。董事会秘书、财务负责 人黄丽计划减持不超过36225股，占总股本的0.0714%。监事余全胜计划减持不超过17525股，占总股本 的0.0345%。监事邹兴平计划减持不超过16000股，占总股本的0.0315%。减持方式均为集中竞价交易， 减持期间为公告发布之日起15个交易日后的三个月内。减持价格将根据市场价格确定，且范德波、付 强、黄丽的减持价格不低于公司首次公开发行股份的发行价。 ...

Group 1 - The core point of the announcement is that Chen Huairong, a shareholder holding 5.52% of the shares, plans to reduce his holdings by up to 7.2744 million shares, which represents 1.38% of the company's total share capital [1] Group 2 - The reduction will take place between June 26, 2025, and September 25, 2025, through centralized bidding or block trading on the stock exchange [1]

广康生化（300804）公告，股东共青城华拓至盈贰号投资合伙企业、深圳市华拓至远投资企业、深圳市 华拓至远贰号投资企业、深圳市华拓至远叁号投资企业计划自公告披露日起的3个交易日后的3个月内通 过集中竞价、大宗交易方式合计减持公司股份不超过222万股，即不超过公司总股本的3.00%。 ...

瑞联新材公告，持股5%以上股东国富永钰计划以集中竞价或大宗交易的方式减持股份不超过573.11万 股，占公司总股本的3.33%。 ...

Core Viewpoint - The major shareholder, Guojiao Beidou (Hainan) Technology Investment Group Co., Ltd., has reduced its stake in Shengyang Technology Co., Ltd. by 2.35%, bringing its total shareholding down to 5.40% after a planned reduction of shares [1][2][3] Shareholder Reduction Details - Before the reduction, Guojiao Beidou held 32,158,000 shares, representing 7.75% of the total share capital [1] - The reduction plan allowed for a maximum of 12,449,463 shares to be sold, equating to 3% of the total share capital, over a period from March 3, 2025, to May 31, 2025 [1] - The actual reduction from May 26 to May 29, 2025, involved selling 5,836,400 shares, which is 1.41% of the total share capital, resulting in a decrease in shareholding from 6.81% to 5.40% [1][2] Reduction Implementation Results - The total shares reduced during the entire plan amounted to 9,735,600 shares, or 2.35% of the total share capital [2] - The reduction was executed through both centralized bidding and block trading, with 3,355,100 shares sold via centralized bidding and 6,380,500 shares through block trading [2] - The reduction occurred within the planned timeframe, and the actual reduction matched the disclosed plan [2][3]

迅捷兴公告，股东淮安市捷兴投资合伙企业(有限合伙)和淮安市迅兴投资合伙企业(有限合伙)计划自公 告披露之日起15个交易日后90日内通过集中竞价交易方式减持不超过133.39万股，占公司总股本比例不 超过1.00%。 ...

Core Viewpoint - The announcement details a significant share reduction by a major shareholder of Tuoxin Pharmaceutical, indicating a shift in ownership structure and potential implications for investor confidence [1][2]. Shareholding Changes - The controlling shareholder, Yang Xining, and his concerted action party, Yiwos Trading Co., Ltd., reduced their stake by 1,019,100 shares, representing 0.81% of the total share capital [1][2]. - Post-reduction, the combined shareholding of Yang Xining and Yiwos decreased from 28.80% to 27.99% [1]. Financial Performance - Tuoxin Pharmaceutical reported a revenue of 422 million yuan for the previous year, a decline of 49.53% year-on-year [2]. - The net profit attributable to shareholders was -19.88 million yuan, compared to a profit of 243 million yuan in the previous year [2]. - The net profit after deducting non-recurring gains and losses was -27.26 million yuan, down from 23.2 million yuan year-on-year [2]. - The net cash flow from operating activities was 103 million yuan, an increase of 280.91% year-on-year [2]. Recent Quarterly Results - In the first quarter of 2025, Tuoxin Pharmaceutical achieved a revenue of 96.99 million yuan, a decrease of 10.46% compared to the same period last year [3]. - The net profit attributable to shareholders was -3.56 million yuan, compared to a profit of 0.21 million yuan in the same quarter last year [3]. - The net cash flow from operating activities was 28.01 million yuan, a decline of 153.72% year-on-year [3]. Dividend Distribution - The board approved a profit distribution plan, proposing no cash dividends or stock bonuses for shareholders [3]. Initial Public Offering (IPO) Details - Tuoxin Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on October 27, 2021, with an initial public offering of 31.5 million shares at a price of 19.11 yuan per share [3]. - The total funds raised amounted to 602 million yuan, with a net amount of 543 million yuan after deducting issuance costs [3][4]. - The funds were intended for projects related to nucleoside series specialty raw materials, pharmaceutical intermediates, and working capital [3].

Core Viewpoint - The article discusses the recent shareholding changes of Su Xin Fund and Zhen Jin Investment in Hao Yuan Pharmaceutical, highlighting their reduction in shareholding and the company's financial performance expectations for 2024 [1][3][4]. Shareholding Changes - Su Xin Fund's shareholding has decreased to 10.548 million shares, representing 5% of the company, thus no longer being a major shareholder [1] - Su Xin Fund plans to reduce up to 6.3288 million shares, accounting for 3% of the total share capital, from March 18 to June 17 [2] - Zhen Jin Investment has completed its reduction of 3.1955 million shares, which is 1.51% of the total share capital, from February 28 to May 22 [2][3] Financial Performance Expectations - Hao Yuan Pharmaceutical anticipates a revenue of CNY 2.1 billion to CNY 2.3 billion for 2024, reflecting a year-on-year growth of 11.70% to 22.34% [4] - The expected net profit attributable to shareholders is projected to be between CNY 185 million and CNY 210 million, indicating a growth of 45.16% to 64.77% [4] - The company attributes its profit growth to the strong performance of its high-margin life science reagent business, which has seen an increase in revenue share compared to 2023 [4] Market Performance - As of May 30, Hao Yuan Pharmaceutical's stock price increased by 15.26% to CNY 44.10 per share, with a market capitalization of CNY 9.303 billion, and has risen over 107% in the past year [5] - The stock's trading volume on the last trading day was 13.5295 million shares, with a turnover rate of 6.56% [6]

Core Viewpoint - Filinger Home Technology Co., Ltd. is undergoing a potential change in control as its actual controller, Ding Furui, is planning to transfer shares, which may lead to a shift in company governance [1][4]. Group 1: Company Overview - Filinger was listed in 2017 and primarily engages in the production and after-sales service of solid wood and composite flooring, with its main brand being "Filinger" [3]. - The largest shareholder is Filinger Holdings Ltd., a foreign entity, holding 28.04% of the shares, while Ding Furui and his associates collectively hold 44.56% [3]. Group 2: Financial Performance - The company has experienced a continuous decline in performance, transitioning from profit to loss. Revenue figures from 2020 to 2024 are as follows: 602 million, 782 million, 523 million, 395 million, and 336 million yuan, with net profits of 60.88 million, 20.33 million, 9.72 million, -24.18 million, and -37.31 million yuan respectively [4]. - The decline in performance is attributed to reduced home decoration demand due to the real estate market adjustment, intensified product price competition, insufficient orders, and high overall production costs [4]. Group 3: Shareholder Dynamics - The decline in performance has led to escalating conflicts between foreign shareholders and Ding Furui, with the German chairman frequently abstaining from board votes. There have also been multiple resignations among the company's directors and executives [5]. - Filinger Holdings Ltd. plans to reduce its stake by up to 10.66 million shares, representing 3% of the total share capital, while other executives also plan to sell portions of their shares [5]. Group 4: Regulatory Issues - Ding Furui and the company faced regulatory scrutiny from the China Securities Regulatory Commission for failing to disclose related party transactions properly, which involved significant contracts with associated companies [6][7]. - The contracts in question had values of 91.78 million yuan and 200 million yuan, constituting 9.97% and 21.73% of the company's latest audited net assets, respectively [6][7].